AtaiBeckley (ATAI) Current Leases (2022 - 2023)

AtaiBeckley's (ATAI) quarterly Current Leases came in at $292000.0 in Q3 2023, down 9.32% quarter-over-quarter from $322000.0 in Q2 2023.

AtaiBeckley (ATAI) Current Leases (2022 - 2023) Analysis & Trends

AtaiBeckley has disclosed Current Leases across 2 years of filings, most recently posting $292000.0 for Q3 2023.

Current Leases for Q3 2023 came in at $292000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was $292000.0 (changed N/A YoY), and the FY2022 annual result was $180000.0, changed N/A from the prior year.
Current Leases came in at $292000.0 for Q3 2023 at AtaiBeckley, down from $322000.0 in the prior quarter.
In the past five years, Current Leases ranged from a high of $322000.0 in Q2 2023 to a low of $180000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	42,980.09
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	83,991.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	7.40 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	AtaiBeckley	1.45 Bn	1.45 Bn	-	-

Download Data